Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. tax change to help Roche's 2018 profit growth outpace sales

02/01/2018 | 05:32am EDT
The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel

BASEL, Switzerland (Reuters) - Swiss drugmaker Roche (>> Roche Holding Ltd.) forecast on Thursday that U.S. tax changes would help profit growth outstrip sales in 2018, while new drugs for multiple sclerosis and cancer would offset revenue declines from older medicines.

BASEL, Switzerland (Reuters) - Swiss drugmaker Roche (>> Roche Holding Ltd.) forecast on Thursday that U.S. tax changes would help profit growth outstrip sales in 2018, while new drugs for multiple sclerosis and cancer would offset revenue declines from older medicines.

Roche said it expected sales to stay flat or grow by a low-single-digit percentage. However, core earnings per share were targeted to grow by a high-single-digit, helped by U.S. tax reform that will reduce Roche's tax rate from 26.6 percent in 2017 to "the low twenties".

Tax changes under U.S. President Donald Trump have had a big impact on investor sentiment towards drugmakers in recent weeks, with AbbVie's (>> AbbVie) stock rising after it projected a big benefit, while Pfizer's (>> Pfizer) was hit by disappointment its tax rate would not be lower.

Excluding the tax changes, profit would grow in line with sales, Roche said, as chief executive Severin Schwan confirmed the drugmaker expected to boost sales and profit even as its $22.5 billion-per-year drugs trio of Rituxan, Herceptin and Avastin faces increasing competition from cheaper copies following patent losses.

"While we are ... facing the entry of biosimilars for important medicines, the strength of our portfolio and the success of our recent launches makes us confident we can compensate for this impact," Schwan told reporters.

"There is definitely the chance that we will not simply compensate for biosimilars, but that we will be able to overcompensate with our new drugs."

Schwan highlighted new medicines including Ocrevus for multiple sclerosis, cancer immunotherapy Tecentriq and lung cancer drug Alecensa, which together contributed 1.4 billion Swiss francs (£1.1 billion) of new sales in 2017.

Total sales increased in 2017 by 5 percent to 53.3 billion francs, close to the average estimate in a Reuters poll of analysts.

Net income under IFRS accounting standards dropped to 8.8 billion francs from 9.7 billion francs a year earlier as Roche took charges including for its lung medicine Esbriet, which was hit by sluggish sales in early treatment indications.

Roche, whose impairments on intangible assets more than doubled to 3.5 billion francs, spent $8.3 billion in 2014 to buy InterMune, which sells Esbriet.

Some analysts said Roche's guidance was conservative and could set up positive surprises later, like in 2017 when Roche raised its sales forecast. Others cautioned the tax benefits could not mask the growing pressure from biosimilars.

"Despite a U.S. tax benefit that was indeed much better than consensus had expected, Roche’s weak underlying 2018 guidance of sales and core EPS ‘stable to low single digit’ growth will likely not be taken well," Kepler analysts wrote in a note to investors. They have a "hold" rating on the shares.


Shares in Roche, whose Genentech unit in the United States generates much of its sales and profit, handed back early gains to trade down 0.5 percent at 0930 GMT.

The Basel-based company's shares are flat over the last 12 months, trailing cross-town rival Novartis (>> Novartis), whose stock has gained 16 percent.

Roche proposed raising its dividend to 8.30 francs per share, below analysts' average forecast of 8.45 francs. It said it aimed to raise the payout again this year.

Among key drugs, top seller Rituxan for blood cancer rose just 1 percent to 7.4 billion francs. Growth in the United States just offset an 11 percent drop in Europe as rivals including Novartis introduce copies.

Avastin, whose patents don't expire until 2019, still dropped 2 percent to 6.7 billion francs as some U.S. lung cancer patients switched to Merck's (>> Merck and Company) Keytruda and French authorities stopped reimbursing for breast cancer, Roche Pharmaceuticals Division chief Dan O'Day said.

Herceptin rose 3 percent to 7 billion francs, while Perjeta rose 19 percent to 2.2 billion francs.

Schwan said the U.S. tax changes would "without a doubt" underpin the strength of the world's largest economy. "You cannot underestimate the impact of the U.S. tax reform on the country's competitiveness," he said.

(Editing by Alexander Smith and Mark Potter)

By John Miller

Stocks treated in this article : Merck and Company, Roche Holding Ltd., Novartis, AbbVie, Pfizer

ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.50% 118.55 Delayed Quote.10.64%
CHANGE INC. -2.72% 2611 End-of-day quote.-25.93%
DEERE & COMPANY 0.01% 353.56 Delayed Quote.31.40%
MERCK & CO., INC. 0.62% 78.33 Delayed Quote.-4.24%
NOVARTIS AG -0.08% 83.95 Delayed Quote.0.39%
PFIZER, INC. 3.21% 43.45 Delayed Quote.18.04%
ROCHE HOLDING AG 0.43% 349.2 Delayed Quote.12.49%
SWISS RE LTD 1.05% 84.96 Delayed Quote.0.84%
All news about ABBVIE INC.
07/27Amgen to Buy Teneobio; Deal Includes $900 Million Upfront, Potential Mileston..
07/27ABBVIE : Truist Assumes Coverage of AbbVie With Buy Rating, $118 Price Target
07/27ABBVIE : Calico Extend Collaboration on Age-Related Diseases
07/27ABBVIE : and Calico Announce Second Extension of Collaboration Focused on Aging ..
07/27AbbVie and Calico Life Sciences Announces Second Extension of Collaboration F..
07/26ABBVIE : New Data Presented on the Safety and Efficacy of Investigational AGN-19..
07/26AbbVie Eye Drug AGN-190584 Meets Endpoints in Phase 3 Study
07/26ABBVIE : Presents Favorable Safety, Efficacy Data on Treatment for Presbyopia
07/23ABBVIE : Wins FDA Approval for Dalvance in Treating Acute Bacterial Skin, Skin S..
07/23ABBVIE : DALVANCE« (dalbavancin) Receives FDA Approval to Treat Acute Bacterial ..
More news
Financials (USD)
Sales 2021 55 876 M - -
Net income 2021 13 834 M - -
Net Debt 2021 63 665 M - -
P/E ratio 2021 15,1x
Yield 2021 4,35%
Capitalization 209 B 209 B -
EV / Sales 2021 4,89x
EV / Sales 2022 4,36x
Nbr of Employees 48 000
Free-Float 98,0%
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 118,55 $
Average target price 122,99 $
Spread / Average Target 3,75%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.10.64%209 386
JOHNSON & JOHNSON9.40%454 682
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.18.04%235 663
NOVARTIS AG-0.44%221 987